1. Holmes RS, Vaughan TL (2007): Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007; 17: 2-9.
2.
Umar SB, Fleischer DE (2008): Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol 5: 517-526.
3.
Kollarova H, Machova L, Horakova D, et al. (2007): Epidemiology of esophageal cancer – an overview article. Biomed Pap Med Fac Palacky Olomouc Czech Repub 151: 17-20.
4.
Torre L, Bray F, Siegel R, et al. (2015): Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108.
5.
He H, Chen N, Hou Y, et al. (2020): Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. Thorac Cancer 11: 1121-1128.
6.
Marabotto E, Pellegatta G, Sheijani AD, et al. (2021): Prevention strategies for esophageal cancer – an expert review. Cancers (Basel) 13: 2183.
7.
Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013): Oesophageal carcinoma. Lancet 381: 400-412.
8.
Abnet CC, Corley DA, Freedman ND, Kamangar F (2015): Diet and upper gastrointestinal malignancies. Gastroenterology 148: 1234-1243.e4.
9.
Ohashi S, Miyamoto Si, Kikuchi O, et al. (2015): Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology 149: 1700-1715.
10.
Rubenstein JH, Shaheen NJ (2015): Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology 149: 302-317.e1.
11.
Wang R, Liu S, Chen B, Xi M (2022): Recent advances in combination of immunotherapy and chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancers 14: 5168.
12.
Zaidi N, Kelly RJ (2017): The management of localized esophageal squamous cell carcinoma: Western approach. Chin Clin Oncol 6: 46.
13.
Zhang Z, Ye J, Li H, et al. (2022): Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial. Front Immunol 13: 1031171.
14.
Noordzij IC, Curvers WL, Schoon EJ (2019): Endoscopic resection for early esophageal carcinoma. J Thorac Dis 11 (Suppl 5): S713.
15.
Guerriero JL, Ditsworth D, Fan Y, et al. (2008): Chemotherapy induces tumor clearance independent of apoptosis. Cancer Res 68: 9595-9600.
16.
Li YJ, Lei YH, Yao N, et al. (2017): Autophagy and multidrug resistance in cancer. Chin J Cancer 36: 52.
17.
Shipitsin M, Campbell LL, Argani P, et al. (2007): Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
18.
Kakeji Y, Oshikiri T, Takiguchi G, et al. (2021): Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy. Esophagus 18: 25-32.
19.
Kano K, Aoyama T, Yoshikawa T, et al. (2018): The negative survival impact of infectious complications after surgery is canceled out by the response of neoadjuvant chemotherapy in patients with esophageal cancer. Ann Surg Oncol 25: 2034-2043.
20.
Kita R, Miyata H, Sugimura K, et al. (2021): Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer. Clin Nutr 40: 4380-4385.
21.
Mazaki T, Ebisawa K (2008): Enteral versus parenteral nutrition after gastrointestinal surgery: a systematic review and meta-analysis of randomized controlled trials in the English literature. J Gastrointest Surg 12: 739-755.
22.
Ryan AM, Reynolds JV, Healy L, et al. (2009): Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg 249: 355-363.
23.
Healy LA, Ryan A, Doyle SL, et al. (2017): Does prolonged enteral feeding with supplemental omega-3 fatty acids impact on recovery post-esophagectomy: results of a randomized double-blind trial. Ann Surg 266: 720-728.
24.
Murphy RA, Mourtzakis M, Chu QS, et al. (2011): Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117: 1775-1782.
25.
Silva JdAP, de Souza Fabre ME, Waitzberg DL (2015): Omega-3 supplements for patients in chemotherapy and/or radiotherapy: A systematic review. Clin Nutr 34: 359-366.
26.
Sultan J, Griffin S, Di Franco F, et al. (2012): Randomized clinical trial of omega-3 fatty acid-supplemented enteral nutrition versus standard enteral nutrition in patients undergoing oesophagogastric cancer surgery. Br J Surg 99: 346-355.
27.
Bolger JC, Donohoe CL, Lowery M, Reynolds JV (2022): Advances in the curative management of oesophageal cancer. Br J Cancer 126: 706-717.
28.
Yang YM, Hong P, Xu WW, et al. (2020): Advances in targeted therapy for esophageal cancer. Signal transduction and targeted therapy. Signal Transduct Target Ther 5: 229.
29.
Barsouk A, Rawla P, Hadjinicolaou AV, et al. (2019): Targeted therapies and immunotherapies in the treatment of esophageal cancers. Med Sci (Basel) 7: 100.
30.
Noori M, Yousefi A, Zali M, Bashash D. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis. Front Oncol 2022; 12: 1021859.
31.
Sharpe AH, Pauken KE (2018): The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18: 153-167.
32.
Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, et al. (2021): Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov 11: 1353-1367.
33.
Hato SV, Khong A, de Vries IJM, Lesterhuis WJ (2014): Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 20: 2831-2837.
34.
Yamamoto S, Kato K (2020): Pembrolizumab for the treatment of esophageal cancer. Expert Opin Biol Ther 20: 1143-1150.
35.
Harada K, Yamamoto S, Kato K (2022): Pembrolizumab for the treatment of advanced esophageal cancer. Future Oncol 18: 2311-2319.
36.
Hirose T, Yamamoto S, Kato K (2023): Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. Therap Adv Gastroenterol 16: 17562848221148250.
37.
Muro K, Hamaguchi T, Ohtsu A, et al. (2004): A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15: 955-959.
38.
Abdo J, Agrawal DK, Mittal SK (2017): Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Rev Anticancer Ther 17: 33-45.
39.
Valkema M, Mostert B, Lagarde S, et al. (2023): The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction. Updates Surg 75: 313-323.
40.
Bando H, Kotani D, Tsushima T, et al. (2020): TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. BMC Cancer 20: 336.
41.
He S, Xu J, Liu X, Zhen Y (2021): Advances and challenges in the treatment of esophageal cancer. Acta Pharm Sin B 11: 3379-3392.
42.
Zhang B, Wang X, Li Q, et al. (2019): Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 anti- body in patients with advanced esophageal squamous cell carcinoma. Chin J Cancer Res 31: 910-917.
43.
Overman MJ, Lonardi S, Wong KYM, et al. (2019): Nivolumab (NIVO)+ low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up. Am Soc Clin Oncol 37: 635.
44.
Eso Y, Seno H (2020): Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therap Adv Gastroenterol 13: 1756284820948773.
45.
Kudo M (2018): Systemic therapy for hepatocellular carcinoma: latest advances. Cancers (Basel) 10: 412.
46.
Wainberg Z, Matos I, Delord J, et al. (2021): LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Ann Oncol 32: S227-S228.
47.
van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. (2021): Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase II feasibility trial (PERFECT) neoadjuvant PD-L1 inhibition for resectable esophageal adenocarcinoma. Clin Cancer Res 27: 3351-3359.
48.
van den Ende T, Menting SP, Ambarus CA, et al. (2019): Cutaneous toxicity after chemoradiotherapy and PD-L1 inhibition in two patients with esophageal adenocarcinoma: More than meets the eye. Oncologist 24: e149-e153.
49.
Patel MR, Ellerton J, Infante JR, et al. (2018): Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19: 51-64.
50.
Li J, Ma S (2021): History and current situation of neoadjuvant treatment for locally advanced esophageal cancer. Thorac Cancer 12: 2293-2299.
51.
Högner A, Thuss-Patience P (2021): Immune checkpoint inhibition in oesophago-gastric carcinoma. Pharmaceuticals (Basel) 14: 151.
52.
Bang YJ, Ruiz EY, Van Cutsem E, et al. (2018): Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol 29: 2052-2060.
53.
Apolo AB, Ellerton JA, Infante JR, et al. (2020): Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer 8: e001246.
54.
Chung HC, Arkenau HT, Lee J, et al. (2019): Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer 7: 1-10.
55.
Apolo AB, Ellerton JA, Infante JR, et al. (2017): Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study. Am Soc Clin Oncol 35, 15_suppl: 4528.
56.
Mikuni H, Yamamoto S, Kato K (2021): Nivolumab for the treatment of esophageal cancer. Expert Opin Biol Ther 21: 697-703.
57.
Yamamoto S, Kato K, Daiko H, et al. (2020): Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol 16: 1351-1357.
58.
Hindson J (2021): Adjuvant nivolumab for resected gastroesophageal cancer. Nat Rev Gastroenterol Hepatol 18: 368.
59.
Blum Murphy M, Xiao L, Patel VR, et al. (2017): Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival – The University of Texas MD Anderson Cancer Center experience. Cancer 123: 4106-4113.
60.
Kelly RJ, Ajani JA, Kuzdzal J, et al. (2021): Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384: 1191-1203.
61.
Kang YK, Boku N, Satoh T, et al. (2017): Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471.
62.
Kato K, Cho BC, Takahashi M, et al. (2019): Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20: 1506-1517.
63.
Lei M, Siemers N, Pandya D, et al. (2019): Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO)±ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC). Cancer Res 79 (13_Supplement): 2673.
64.
Weber J, Mandala M, Del Vecchio M, et al. (2017): Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377: 1824-1835.
65.
Janjigian YY, Bendell J, Calvo E, et al. (2018): CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36: 2836-2844.
66.
Kudo T, Hamamoto Y, Kato K, et al. (2017): Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 18: 631-639.
67.
Cooper JS, Guo MD, Herskovic A, et al. (1999): Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281: 1623-1627.
68.
Suntharalingam M, Winter K, Ilson D, et al. (2017): Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol 3: 1520-1528.
69.
Zhang W, Yan C, Gao X, et al. (2021): Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma. Oncologist 26: e1110-e1124.
70.
Hua Y, Huang X, Li C, Gao N (2023): An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report. Oral Oncol 140: 106369.
71.
Huang J, Xu J, Chen Y, et al. (2020): Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 21: 832-842.
72.
Luo H, Lu J, Bai Y, et al. (2021): Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326: 916-925.
73.
Lee A, Keam SJ (2020): Tislelizumab: first approval. Drugs 80: 617-624.
74.
Pinato DJ, Fessas P, Sapisochin G, Marron TU (2021): Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma. Hepatology 74: 483-490.
75.
Wang HY, Yao ZH, Tang H, et al. (2006): Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Onco Targets Ther 9: 5663-5669.
76.
Ychou M, Boige V, Pignon JP, et al. (2011): Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29: 1715-1721.
77.
Soror T, Kho G, Zhao KL, et al. (2018): Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 10: 4069-4076.
78.
Yan X, Duan H, Ni Y, et al. (2022): Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). Int J Surg 103: 106680.
79.
Yamamoto S, Kato K (2020): Immuno-oncology for esophageal cancer. Future Oncol 16: 2673-2681.
80.
Feng Y, Hong Y, Sun H, et al. (Eds.) (2019): The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab. proceedings of the 110th annual meeting of the American association for cancer research. American Association of Cancer Research, Atlanta, GA.
81.
Xu J, Bai Y, Xu N, et al. (2020): Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma. Clin Cancer Res 26: 4542-4550.
82.
Xu JM, Kato K, Hubner R, et al. (2019): A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC). J Clin Oncol 37.
83.
Cowzer D, Wu AJC, Sihag S, et al. (2023): Durvalumab and pet-directed chemoradiation in locally advanced esophageal adenocarcinoma – a phase Ib/II study. Ann Surg 278: e511-e518.
84.
Janjigian YY, Van Cutsem E, Muro K, et al. (2022): MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol 18: 2465-2473.
85.
Antonia SJ, Villegas A, Daniel D, et al. (2017): Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377: 1919-1929.
86.
Abou-Alfa GK, Chan SL, Kudo M, et al. (2022): Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol 40.
87.
Paz-Ares L, Chen Y, Reinmuth N, et al. (2021): LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Ann Oncol 32: S1338.
88.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. (2018): Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 378: 2078-2092.
89.
Janjigian YY, Shitara K, Moehler M, et al. (2021): First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398: 27-40.
90.
Li JY, Chen YP, Li YQ, et al. (2021): Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer 20: 1-21.
91.
Bang YJ, Kang YK, Catenacci DV, et al. (2019): Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer 22: 828-837.
92.
Stewart R, Morrow M, Hammond SA, et al. (2015): Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody identification and characterization of MEDI4736. Cancer Immunol Res 3: 1052-1062.
93.
Antonia S, Goldberg SB, Balmanoukian A, et al. (2016): Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17: 299-308.
94.
Hollebecque A, Wainberg ZA, Ajani JA, et al. (2018): Safety and clinical activity of durvalumab monotherapy in patients with gastroesophageal cancers. J Clin Oncol 36.
95.
Kelly RJ, Lee J, Bang YJ, et al. (2020): Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. Clin Cancer Res 26: 846-854.
96.
Khoja L, Day D, Chen TWW, et al. (2017): Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28: 2377-2385.
97.
Thompson JA, Schneider BJ, Brahmer J, et al. (2019): Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17: 255-289.
98.
Jin G, Guo S, Zhang Y, et al. (2021): Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 39 (15 Suppl): 4138.
99.
Lisi L, Lacal PM, Martire M, et al. (2022): Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacol Res 175: 105997.
100.
Sugawara K, Iwai M, Ito H, et al. (2021): Oncolytic herpes virus G47 works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. Mol Ther Oncolytics 22: 129-142.
101.
Price KD, Simutis F, Fletcher A, et al. (Eds.) (2018): Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys. Molecular cancer therapeutics, Philadelphia, PA.
102.
Feng Y, Li C, Ji Y, et al. (2022): Nivolumab combined with ipilimumab treatment induced hypophysitis and immune-mediated liver injury in advanced esophageal squamous cell carcinoma: A case report. Front Oncol 12: 1309.
103.
Vaddepally RK, Kharel P, Pandey R, et al. (2020): Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12: 738.
104.
Shah MA, Kojima T, Hochhauser D, et al. (2019): Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol 5: 546-550.
105.
Zhu Y, Liu K, Ding D, et al. (2022): Pembrolizumab plus chemotherapy as first-line treatment for advanced esophageal cancer: A cost-effectiveness analysis. Adv Ther 39: 2614-2629.
106.
Muro K, Kojima T, Moriwaki T, et al. (2022): Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus 19: 137-145.
107.
Kojima T, Muro K, Francois E, et al. (2019): Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol 37.
108.
Kojima T, Shah MA, Muro K, et al. (2020): Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 38: 4138-4148.
109.
Habu T, Kumanishi R, Ogata T, et al. (2023): Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma. Esophagus 20: 533-540.
110.
Blum Murphy MA, Nogueras Gonzalez GM, Sewastjanow-Silva M, et al. (2023): Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma. J Clin Oncol 41.
111.
Hamilton G (2021): Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. Expert Opin Biol Ther 21: 311-322.
112.
Uboha NV, Maloney JD, McCarthy D, et al. (2019): Phase I/II trial of perioperative avelumab in combination with chemoradiation in the treatment of stage II/III resectable esophageal cancer. J Clin Oncol 37.
113.
Uboha NV, Eickhoff JC, Maloney JD, et al. (2022): Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer. J Clin Oncol 40.
114.
Leone A, Petrelli F, Ghidini A, et al. (2022): Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score. ESMO Open 7: 100380.
115.
Okada M, Yamamoto S, Kato K (2020): Nivolumab for the treatment of esophageal squamous cell carcinoma. N Engl J Med 386: 449-462.
116.
Li ZC, Sun YT, Lai MY, et al. (2022): Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis. Int Immunopharmacol 109: 108790.
117.
Huang RW, Chao YK, Wen YW, et al. (2014): Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. World J Surg Oncol 12: 170.
118.
Kulangara K, Guerrero L, Posch A, et al. (2018): Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS). J Clin Oncol 36.
119.
Cunningham D, Allum WH, Stenning SP, et al. (2006): Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20.
120.
Doki Y, Ueno M, Hsu CH, et al. (2022): Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med 11: 2550-2560.
121.
Zhang C, Chen J, Song Q, et al. (2020): Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer types. Int Immunopharmacol 85: 106633.
122.
Hodi FS, O’Day SJ, McDermott DF, et al. (2010): Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
123.
Borghaei H, Paz-Ares L, Horn L, et al. (2015): Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639.
124.
Janjigian YY, Bendell JC, Calvo E, et al. (2016): CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol 34.
125.
Motzer RJ, Escudier B, McDermott DF, et al. (2015): Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1803-1813.
126.
Robert C, Long GV, Brady B, et al. (2015): Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320-330.
127.
Weber JS, Gibney G, Sullivan RJ, et al. (2016): Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 17: 943-955.
128.
Hayashi H, Nakagawa K (2020): Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol 25: 818-830.
129.
Kooshkaki O, Derakhshani A, Hosseinkhani N, et al. (2020): Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials. Int J Mol Sci 21: 4427.
